Ieki K, Yazaki Y, Yamaoki K, Tsuchimochi H, Yoshizumi M, Komuro I, Sugiyama T, Seko Y, Takaku F, Kojima M
Third Department of Internal Medicine, University of Tokyo, Japan.
J Mol Cell Cardiol. 1989 Dec;21 Suppl 5:113-9. doi: 10.1016/0022-2828(89)90777-3.
Recent studies suggest that beta-blocker treatment may attenuate cardiac hypertrophy induced by pressure overload in the spontaneously hypertensive rat (SHR), but the effect of this therapy on the reconstitution of the intracellular constituents in the heart that occurs during the development of cardiac hypertrophy has not been examined. In this study, we investigated the effect of chronic administration of carteolol (4 mg/kg/day p.o.) or propranolol (20 mg/kg/day p.o.), beta-blockers with distinct modes of action, on the composition of cardiac myosin isozymes and histological findings as well as heart weight. Therapeutic periods were 4, 12 or 30 weeks. Though blood pressure was not significantly reduced, the development of cardiac hypertrophy was suppressed as evidenced by left ventricular weight in both groups of carteolol- and propranolol-treated SHR for all therapeutic periods. Again, beta-blocker treatment for 12 weeks alleviated myocardial degeneration and reactive fibrosis which were observed in all cases of age-matched untreated SHR. However the extent of the transition of cardiac myosin isozymes from V1 to V2 or V3 were essentially the same among all groups including untreated SHR. These results indicate that chronic administration of beta-blockers attenuates the development of cardiac hypertrophy and degeneration without affecting the transition of myosin isozymes which is thought to be a kind of biochemical adaptation of the myocardium to overload.
最近的研究表明,β受体阻滞剂治疗可能会减轻自发性高血压大鼠(SHR)压力超负荷诱导的心脏肥大,但这种疗法对心脏肥大发展过程中发生的心脏细胞内成分重构的影响尚未得到研究。在本研究中,我们研究了长期口服卡替洛尔(4mg/kg/天)或普萘洛尔(20mg/kg/天)这两种作用方式不同的β受体阻滞剂,对心肌肌球蛋白同工酶组成、组织学结果以及心脏重量的影响。治疗期为4周、12周或30周。尽管血压没有显著降低,但在所有治疗期,卡替洛尔和普萘洛尔治疗的SHR组中,左心室重量证明心脏肥大的发展受到抑制。同样,12周的β受体阻滞剂治疗减轻了在所有年龄匹配的未治疗SHR病例中观察到的心肌变性和反应性纤维化。然而,在所有组中,包括未治疗的SHR,心肌肌球蛋白同工酶从V1向V2或V3转变的程度基本相同。这些结果表明,长期给予β受体阻滞剂可减轻心脏肥大和变性的发展,而不影响肌球蛋白同工酶的转变,后者被认为是心肌对超负荷的一种生化适应。